Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mesenchymal Stem Cells

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Proinflammatory cytokines sensitise mesenchymal stromal cells to apoptosis.

Cell death discovery·2025

Same author

Subcutaneous delivery of mesenchymal stromal cells induces immunoregulatory effects in the lymph node prior to their apoptosis.

Stem cell research & therapy·2024

Same author

Stem Cell Derived Extracellular Vesicle Therapy for Multiple Sclerosis, A Systematic Review and Meta-Analysis of Preclinical Studies.

Stem cells translational medicine·2024

Same author

Nogo receptor-Fc delivered by haematopoietic cells enhances neurorepair in a multiple sclerosis model.

Brain communications·2023

Same author

Secondary Lymphoid Organs in Mesenchymal Stromal Cell Therapy: More Than Just a Filter.

Frontiers in immunology·2022

Same author

Clinically relevant T cell expansion media activate distinct metabolic programs uncoupled from cellular function.

Molecular therapy. Methods & clinical development·2022

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Assessment of the Immunomodulatory Properties of Human Mesenchymal Stem Cells (MSCs)

Assessment of the Immunomodulatory Properties of Human Mesenchymal Stem Cells (MSCs)

Published on: December 24, 2015

A consensus statement addressing mesenchymal stem cell transplantation for multiple sclerosis: it's time!

Christopher Siatskas¹, Natalie L Payne, Martin A Short

¹Monash immunology and stem cell laboratories, Monash University, Clayton, Victoria, 3800, Australia. christopher.siatskas@monash.edu

Stem Cell Reviews and Reports

|July 29, 2010

Summary

This summary is machine-generated.

Mesenchymal stem cells (MSCs) show promise for treating multiple sclerosis (MS) by reducing inflammation and protecting the nervous system. Clinical trials are underway to evaluate their safety and efficacy in MS patients.

More Related Videos

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

Related Experiment Videos

Last Updated: Jun 10, 2026

Assessment of the Immunomodulatory Properties of Human Mesenchymal Stem Cells (MSCs)

Assessment of the Immunomodulatory Properties of Human Mesenchymal Stem Cells (MSCs)

Published on: December 24, 2015

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

Area of Science:

Neuroscience
Immunology
Regenerative Medicine

Background:

Multiple sclerosis (MS) is a neurodegenerative disease characterized by inflammation and axonal loss.
Current MS treatments primarily target inflammation, with limited impact on neurodegeneration and permanent disability.
Mesenchymal stem cells (MSCs) possess immune-regulatory and neuroprotective properties, making them a potential therapeutic approach for MS.

Purpose of the Study:

To evaluate the potential of Mesenchymal stem cells (MSCs) as a therapeutic strategy for multiple sclerosis (MS).
To summarize the preclinical and clinical findings regarding MSC transplantation in MS.
To establish a consensus for the use of autologous bone marrow-derived MSCs in MS treatment.

Main Methods:

Preclinical evaluation of MSCs in experimental models of MS.
Assessment of MSC safety in various clinical conditions, including inflammatory diseases.
Initiation of multicenter clinical trials to evaluate MSC safety and efficacy in inflammatory MS.

Main Results:

Preclinical studies demonstrate MSC efficacy in suppressing clinical disease in experimental MS models.
MSC transplantation has been well-tolerated in patients across different disease types, with minimal adverse effects.
Ongoing clinical trials are investigating the safety and effectiveness of MSCs for inflammatory MS.

Conclusions:

Mesenchymal stem cells (MSCs) offer a promising therapeutic avenue for multiple sclerosis (MS) due to their immunomodulatory and neuroprotective effects.
The established safety profile of MSCs supports their continued investigation in clinical trials for MS.
A consensus guide for autologous bone marrow-derived MSC transplantation is being developed, potentially paving the way for next-generation MS therapies.